Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

Nikas, Spyros N.

doi:10.1136/ard.2005.039099

Cited by 98 publications

(61 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There have been trials comparing IV and SC drug administration with most reporting on drug efficacy and safety [7][8][9][10][11][12][13][14][15][16]. In the study by Moreau et al (2011) [11], patients with relapsed multiple myeloma (MM) were randomised to receive bortezomib either by SC administration or IV infusion.…”

Section: Introductionmentioning

confidence: 99%

Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review

Stoner

Harder

Fallowfield

et al. 2014

Patient

121

102

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review

Stoner

Harder

Fallowfield

et al. 2014

Patient

121

102

View full text Add to dashboard Cite

show abstract

“…In individual patients, these differences may explain the differential response to the 3 agents, although there is no direct evidence to support this. Indeed, there are now numerous reports in which it has been suggested that initiating therapy with a second anti-TNF␣ agent in patients who have failed therapy with a first agent (due to lack of efficacy or because of an AE) may be beneficial and not associated with an increased rate of AEs with the second agent (12)(13)(14)(15)(16)(17)(18)(19)(20). However, all of the studies to date have been based on small case series (the largest included only 37 patients), which makes it difficult to establish a substantive estimate of recurrent AEs and treatment inefficacy.…”

mentioning

confidence: 99%

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

Hyrich

Lunt

Watson

et al. 2007

Arthritis & Rheumatism

379

215

View full text Add to dashboard Cite

Objective. Patients with rheumatoid arthritis (RA) who experience treatment failure with one antitumor necrosis factor (anti-TNF) agent, due to either inefficacy or toxicity, are frequently switched to a second anti-TNF agent, although the benefits of switching are unknown. The present study was undertaken to compare drug continuation rates between the first course and second course of anti-TNF therapy.Methods. The study involved a prospective cohort of RA patients from a UK national register of new anti-TNF treatment starts (n ‫؍‬ 6,739; 876 starting adalimumab, 2,826 starting etanercept, and starting 3,037 infliximab). Over a mean 15 months of followup, 841 patients stopped taking the first drug due to inefficacy and 1,023 stopped the first drug due to toxicity, of whom 503 and 353, respectively, were switched to a second anti-TNF agent. Kaplan-Meier survival curves were plotted to determine continuation rates for each course, and Cox regression was used to compare each course for the risk of stopping and the reason for stopping (inefficacy or toxicity).Results. Overall, 73% of patients who switched to a second anti-TNF agent remained on the new therapy by the end of followup. First drug discontinuation due to inefficacy was associated with an increased rate of second drug discontinuation due to inefficacy (hazard ratio [HR] 2.7, 95% confidence interval [95% CI] 2.1-3.4) but not toxicity (HR 1.1, 95% CI 0.9-1.5). Similarly, first drug discontinuation due to toxicity was associated with an increased rate of second drug discontinuation due to toxicity (HR 2.3, 95% CI 1.9-2.9) but not inefficacy (HR 1.2, 95% CI 0.8-1.6).Conclusion. RA patients who are switched to a second anti-TNF drug have high rates of continuation, although among those who must discontinue treatment, the reasons for stopping a second drug are related to the reasons for stopping the first drug. This large data set from the UK provides the first estimates of the magnitude of these effects in patients with long-standing severe RA.

show abstract

“…Нежелательные явления включали в себя локальные кожные реакции в месте введения. Применение адалимумаба не сопровождалось летальными исходами и не требовало отмены препарата из-за нежелательных явлений [10,14].…”

Section: обмен опытомunclassified

“…Результаты контролируемых клинических и открытых исследований позволяют заключить, что подкожное вве-дение адалимумаба эффективно и безопасно как при РА, анкилозирующем спондилите и псориатическом артрите у взрослых пациентов [10][11][12][13][14][15][16][17][18][19][20][21][22], так и при ЮИА у детей [23][24][25][26][27][28][29][30][31][32][33][34][35]. Соответственно, в случае первичной или вторич-ной неэффективности других генно-инженерных биологи-ческих препаратов переключение на адалимумаб может оказаться перспективным.…”

Section: Introductionunclassified

EFFICACY AND SAFETY OF ANTI-TNFα HUMAN MONOCLONAL ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND SECONDARY RESISTANCE TO OTHER GENETICALLY ENGINEERED BIOLOGICAL AGENTS

Алексеева¹,

Бзарова²,

Валиева³

et al. 2012

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

Cited by 98 publications

References 12 publications

Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review

Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

EFFICACY AND SAFETY OF ANTI-TNFα HUMAN MONOCLONAL ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND SECONDARY RESISTANCE TO OTHER GENETICALLY ENGINEERED BIOLOGICAL AGENTS

Contact Info

Product

Resources

About